Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the first class of glucose-lowering agents associated with a reduced risk for HF in patients with diabetes and a reduced risk for hospitalization owing to HF.
The prevalence of diabetes is similar in HFpEF and HFrEF because the two disorders overlap; diabetes is present in up to 45% of patients with chronic HF, regardless of whether they have reduced or preserved ejection fraction.
In terms of prevalence and its association with clinical outcome, renal dysfunction may be the most important comorbidity in HF. The condition is common with renin-angiotensin-aldosterone system–inhibiting therapy, which is used in most patients with HF. With no evidence-based therapy for these comorbidities, morbidity and mortality in patients with HF and renal dysfunction remains an underappreciated topic.
Available data suggest that intensive glycemic control in patients with diabetes does not lessen the risk for HF.
Learn more about type 2 diabetes treatment and management.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ioana Dumitru. Fast Five Quiz: Heart Failure Comorbidities - Medscape - Jul 15, 2021.